Fu Qiong, Yao Gen-you, Tang Xuan-li, Chen Li-rong, Zheng Zhen-xiao
Department of Pathology, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Zhonghua Zhong Liu Za Zhi. 2007 Jan;29(1):34-40.
To investigate the incidence and clinicopathologic significance of MSI and LOH on 3P in breast carcinoma and its precancerous lesions, intraductal papillary adenoma and ductal carcinoma in situ.
41 paired sporadic invasive breast carcinomas, 13 archival precancerous lesion specimens of the breast and 14 couples of benign hyperplasia were collected. Twelve microsatellites on chromosomes 2p, 3p, 5q, 6q, 16q, 17q, eleven markers on chromosome 3p were amplified for MSI and LOH, respectively, by polymerase chain reaction ( PCR ) with designed primers and detecting after polyacrylamide gel electrophoresis. In addition, the expression of protein of hMSH2, hMLHI, FHIT, ER, and PR were detected by immunohistochemistry.
MSI was observed, at least two microsatellite markers, in 15 out of 41 (36. 6%) of the carcinomas, almost all belonging to poorly or intermediately differentiated carcinoma. Instability was shown in 9 of the 13 cases of precancerous lesions, but only 2 among them had more than 2 MSI sites. There was no MSI in benign hyperplasia. MSI was targeted predominately at D3S1766, D2S2739 in both carcinomas and precancerous lesions. Of the 11 loci examined, D3S1295, D3S1029 and D3S1038 were identified as the locus with most frequent LOH which were all correlated significantly with some clinicopathological parameters such as histological type, lymph node metastasis in breast cancer, while D3S1295 and D3S1029 were the most frequent markers in precancerous lesions. LOH of D3S1295 had significant correlation with negative expression of FHIT. Positive expression of hMLH1 and hMSH2 protein was detected in breast carcinomas in scattered distribution and their positive rate was 45% and 40% , respectively. In precancerous lesions, hMLH1 and hMSH2 protein showed diffuse expression and their positive rate was 61. 54% and 76. 92% , respectively, significantly lower than that in the control tissues.
Defective expression of MMR genes is closely associated with the development of breast cancer. Genomic instability might play a role in the early stage during multi-step mammary carcinogenesis. MSI indicates poor histological differentiation in breast carcinoma. D3S1766 and D2S2739 might be the sensitive sites to detect MSI in breast carcinoma and precancerous lesions. The smallest common LOH deletion regions seem likely to be situated between 3p14 and 3p25, indicating the existence of breast tumor related genes in those regions and some of them might affect tumor development.
探讨微卫星高度不稳定(MSI)及3p上杂合性缺失(LOH)在乳腺癌及其癌前病变导管内乳头状瘤和导管原位癌中的发生率及临床病理意义。
收集41对散发性浸润性乳腺癌、13份存档的乳腺组织癌前病变标本以及14对乳腺良性增生组织。采用聚合酶链反应(PCR),分别用设计的引物对2p、3p、5q、6q、16q、17q染色体上的12个微卫星以及3p染色体上的11个标记进行扩增,用于检测MSI和LOH,扩增产物经聚丙烯酰胺凝胶电泳后进行检测。此外,采用免疫组织化学法检测hMSH2、hMLH1、FHIT、雌激素受体(ER)和孕激素受体(PR)蛋白的表达。
41例乳腺癌中,15例(36.6%)至少有两个微卫星标记出现MSI,几乎均为低分化或中分化癌。13例癌前病变中有9例出现不稳定现象,但其中只有2例有2个以上MSI位点。良性增生组织中未发现MSI。在癌组织和癌前病变中,MSI主要发生在D3S1766、D2S2739。在所检测的11个位点中,D3S1295、D3S1029和D3S1038被确定为LOH最常见的位点,它们均与一些临床病理参数如组织学类型、乳腺癌腋窝淋巴结转移显著相关,而D3S1295和D3S1029是癌前病变中最常见的标记。D3S1295的LOH与FHIT蛋白阴性表达显著相关。hMLH1和hMSH2蛋白在乳腺癌组织中呈散在分布阳性表达,阳性率分别为45%和40%。在癌前病变中,hMLH1和hMSH2蛋白呈弥漫性表达,阳性率分别为61.54%和76.92%,显著低于对照组织。
错配修复(MMR)基因表达缺陷与乳腺癌的发生密切相关。基因组不稳定可能在乳腺癌多步骤发生的早期阶段起作用。MSI提示乳腺癌组织学分化差。D3S1766和D2S2739可能是检测乳腺癌及癌前病变中MSI的敏感位点。最小的常见LOH缺失区域可能位于3p14和3p25之间,提示这些区域存在与乳腺肿瘤相关的基因,其中一些可能影响肿瘤的发生发展。